Drug Type Small molecule drug |
Synonyms Balapiravir, Balapiravir hydrochloride (USAN), R-1626 + [3] |
Target |
Action inhibitors |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H31ClN6O8 |
InChIKeyRAJFQMDUVDHLII-PYZPAVLJSA-N |
CAS Registry690270-65-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Australia | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Austria | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Canada | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | France | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Germany | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Italy | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Puerto Rico | 01 Dec 2007 | |
| Chronic hepatitis C genotype 1 | Phase 2 | Spain | 01 Dec 2007 | |
| Dengue | Phase 1 | Vietnam | 01 Jul 2010 |





